HOME  | FOR PROFESSIONALS HOME  |   SITE MAP  |   CONTACT US  | COMPLIANCE


 

 


                  For Professionals







 


 

 

AXID OS (nizatidine) is a prescription syrup to treat GERD and certain ulcers.  The benefits include:

  • convenient
  • pleasant tasting
  • alcohol-free
  • bubblegum flavored

Axid Oral Solution contains the same active ingredient as Axid capsules that have been used for years by millions of patients.  Axid Oral Solution  has been formulated especially for children and adults who either cannot take the tablets or who prefer a pleasant, bubble gum flavored syrup.

If you or your child experience the signs and symptoms of certain kinds of ulcers or Gastroesophageal Reflux Disease (GERD), Axid Oral Solution  may be prescribed for that treatment by your doctor.

The symptoms of GERD may include but are not limited to:

  • Frequent heartburn
  • Chest pain
  • Belching acid into the mouth
  • Stomach contents going up into the mouth
  • Spitting up
  • Trouble swallowing 

Other conditions may cause similar symptoms, so your doctor will need to diagnose whether or not you have GERD.


 

 

 

 

 

 

 

 


Click here for full prescribing information

 

In pediatric patients AXID Oral Solution is indicated for ages 12 years and older. AXID Oral Solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.

The most common adverse events (>5%) in controlled clinical trials with pediatric patients were pyrexia, nasopharyngitis, diarrhea, vomiting, irritability, nasal congestion, and cough. In controlled clinical trials with adults, anemia (0.2% vs 0%) and urticaria (0.5% vs 0.1%) were significantly more common in the nizatidine group than with placebo. The following treatment-emergent AEs occurred in controlled clinical trials with nizatidine vs placebo in adults: headache (16.6% vs 15.6%), diarrhea (7.2% vs 6.9%), dizziness (4.6% vs 3.8%), and rhinitis (9.8% vs 9.6%).

Symptomatic response to nizatidine therapy does not preclude the presence of gastric malignancy. Pharmacokinetic studies in patients with hepatorenal syndrome have not been done. Part of the dose of nizatidine is metabolized in the liver. AXID Oral Solution is contraindicated in patients with known hypersensitivity to the drug. Because cross sensitivity in this class of components has been observed, H2RAs, including nizatidine, should not be administered to patients with a history of hypersensitivity to other H2RAs. Dosage should be reduced in patients with moderate to severe renal insufficiency including some elderly patients with decreased creatinine clearance.

References: 1. Zantac Syrup full prescribing information. 2. AXID Oral Solution full prescribing information. 3. Pediatric Gastroesophageal Reflux. Clinical Practice Guideline Summary. Available at: http://www.cdhnf.org/pdf/GERD_8_pg_brochure_031103.pdf.  Accessed September 3, 2004.

Zantac is a registered trademark of GlaxoSmithKline.